Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) Equity Average (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Equity Average for 7 consecutive years, with $1.8 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 22.08% year-over-year to $1.8 billion, compared with a TTM value of $1.8 billion through Dec 2025, up 22.08%, and an annual FY2025 reading of $1.6 billion, up 61.68% over the prior year.
  • Equity Average was $1.8 billion for Q4 2025 at Avidity Biosciences, up from $1.5 billion in the prior quarter.
  • Across five years, Equity Average topped out at $1.8 billion in Q4 2025 and bottomed at $275.3 million in Q2 2021.
  • Average Equity Average over 5 years is $777.7 million, with a median of $548.7 million recorded in 2023.
  • Peak annual rise in Equity Average hit 534.52% in 2021, while the deepest fall reached 1.37% in 2021.
  • Year by year, Equity Average stood at $388.2 million in 2021, then increased by 23.03% to $477.5 million in 2022, then grew by 6.61% to $509.1 million in 2023, then surged by 187.59% to $1.5 billion in 2024, then increased by 22.08% to $1.8 billion in 2025.
  • Business Quant data shows Equity Average for RNA at $1.8 billion in Q4 2025, $1.5 billion in Q3 2025, and $1.3 billion in Q2 2025.